Abstract Library

#4105 Long-term outcomes for medically managed carcinoid heart disease patients: A retrospective, longitudinal survey

Introduction: Carcinoid Heart Disease (CHD) is a component of carcinoid syndrome. Patients with mild to moderate CHD and no indication for surgical intervention receive medical management (MMCHD).

Conference:

Presenting Author:

Authors: Fisher J, Montague K, Adigun R, Hayes A, Furtado-O'Mahony L,

Keywords: carcinoid syndrome, carcinoid heart disease, survival, medical management,

#3921 Mixed neuroendocrine-non-neuroendocrine neoplasms of the rectum: A case report

Introduction: Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (MiNEN) represent roughly 1-2% of all colorectal malignancies. Given the rareness and heterogeneity of these mixed tumors, recognition and accurate diagnosis remain a challenge. In the absence of established guidelines, they are treated according to the standard of care for pure neuroendocrine carcinomas or adenocarcinomas from similar sites of origin.

Conference:

Presenting Author: Verdasca F

Authors: Verdasca F, Montenegro A, Mendes J, Furtado I, Ferreira R,

Keywords: mixed neuroendocrine-non-neuroendocrine neoplasms, mixed epithelial endocrine neoplasms, case report, colorectal cancer,

#3759 Long-term outcomes of surgical valve replacement in patients with severe carcinoid heart disease

Introduction: Carcinoid Heart Disease (CHD) is a complex complication of carcinoid syndrome (CS), with Surgical Valve Replacement (SVR) being its established treatment in selected patients.

Conference:

Presenting Author: Hayes A

Authors: Matti J, Crompton J, Furtado O'Mahony L, Hayes A, Harrison T,

Keywords: Carcinoid Heart Disease, Valve Replacement, Carcinoid Syndrome, Overall Survival,

#3756 The clinical utility of NETest in patients with small intestinal neuroendocrine neoplasms (SI-NENs) – A "real-life" study

Introduction: Management of patients with SI-NENs is challenging due to biological heterogeneity. Prognostication can be difficult, mostly due to a lack of reliable biomarkers.

Conference:

Presenting Author:

Authors: Gertner J, Hayes A, Furtado O'Mahony L, Glover T, Karia P,

Keywords: Neuroendocrine neoplasm, small intestine, NETest, tumor growth rate, biomarker,

#3178 Dual 68Ga-DOTATATE and 18F-FDG PET/CT in patients with gastroenteropancreatic neuroendocrine neoplasms: A multicentre, validation study of the NETPET score in 239 patients

Introduction: PET/CT using 68Ga-labelled somatostatin analogues and 18F-FDG have both been used to image neuroendocrine tumors. Our previously published data proposed the NETPET score to characterise findings on dual PET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chan D, Hayes A, Karfis I, Navalkissoor S, Furtado O’Mahony L,

Keywords: NETPET, prognostic biomarker, PET imaging, FDG, 68Ga-DOTATATE,